EVA CASE: Open Payments
NPI 1750820841 · PONCA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,029 in 56 payments from 13 companies in 2025. Trend: 2023 $207 · 2024 $548 · 2025 $1,029
Food & beverage: $1,029
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $285 |
| ABBVIE INC. | 20 | $260 |
| Vanda Pharmaceuticals Inc. | 7 | $137 |
| GlaxoSmithKline, LLC. | 5 | $89 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $57 |
| Lundbeck LLC | 2 | $49 |
| Lilly USA, LLC | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
Products named: BREZTRI, VRAYLAR, FANAPT, TRELEGY ELLIPTA, REXULTI, FARXIGA, CAPLYTA, QULIPTA.
Industry payments across OK — which companies pay providers there.
